A Phase 2b Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat.

Condition:   Subcutaneous Fat Interventions:   Drug: CBL-514 injection;   Drug: CBL-A1 Injection;   Drug: CBL-A2 Injection;   Drug: 0.9% Sodium Chloride Sponsor:   Caliway Biopharmaceuticals Co., Ltd. Not yet recruiting

Source: ClinicalTrials.gov - August 22, 2023 Category: Research Source Type: clinical trials